Survival after Diagnosis of Cervical Cancer Patients at a Tertiary Referral Hospital in Northeast Thailand.


Journal

Asian Pacific journal of cancer prevention : APJCP
ISSN: 2476-762X
Titre abrégé: Asian Pac J Cancer Prev
Pays: Thailand
ID NLM: 101130625

Informations de publication

Date de publication:
01 May 2023
Historique:
received: 29 01 2023
medline: 31 5 2023
pubmed: 29 5 2023
entrez: 29 5 2023
Statut: epublish

Résumé

Cervical cancer (CC) is the third most common cancer in women globally, including Thailand, where the incidence rate was 16.2 cases per 100,000 individuals in 2018. Survival rates for patients with this condition have not improved over recent years. This study evaluated the survival rate and median survival time after diagnosis among CC patients, and investigated factors associated with survival in Northeast Thailand. This study included CC patients admitted to the gynecological ward at Srinagarind Hospital, Faculty of Medicine, Khon Kaen University, Thailand from 2010 to 2019. Survival rates and median survival time since the date of diagnosis and 95% confidence intervals (CIs) were calculated. Multiple cox regression was performed to investigate factors associated with survival which were quantified by adjusted hazard ratios (AHR) and their 95% CIs. Of 2,027 CC patients, the overall mortality incidence rate was 12.44 per 100 person-years (95% CI: 11.7 - 13.22), median survival time was 4.82 years (95% CI: 3.92 - 5.72), and 10-year survival rate was 43.16% (95% CI: 40.71 - 45.59). The highest 10-year survival rate was 87.85% (95% CI: 82.23 - 91.78) found among those with stage I CC, followed by those who received surgical treatment, which was 81.22% (95% CI: 74.47 - 86.35). Factors that were associated with decreased survival included age ≥60 years (AHR = 1.25; 95% CI: 1.07 - 1.46), health insurance with the Universal Health Coverage Scheme (UCS) (AHR = 6.26; 95% CI: 5.13 - 7.64), malignant neoplasms histopathology (AHR = 1.36; 95% CI: 1.07 - 1.74), and treatment with supportive care (AHR = 7.48; 95% CI: 5.22 - 10.71). Among patients diagnosed with CC, those with stage I had the highest 10-year survival rate. CC patients with older age, UCS, malignant neoplasms histopathology, and received supportive care showed the highest survival association.

Sections du résumé

BACKGROUND BACKGROUND
Cervical cancer (CC) is the third most common cancer in women globally, including Thailand, where the incidence rate was 16.2 cases per 100,000 individuals in 2018. Survival rates for patients with this condition have not improved over recent years. This study evaluated the survival rate and median survival time after diagnosis among CC patients, and investigated factors associated with survival in Northeast Thailand.
METHODS METHODS
This study included CC patients admitted to the gynecological ward at Srinagarind Hospital, Faculty of Medicine, Khon Kaen University, Thailand from 2010 to 2019. Survival rates and median survival time since the date of diagnosis and 95% confidence intervals (CIs) were calculated. Multiple cox regression was performed to investigate factors associated with survival which were quantified by adjusted hazard ratios (AHR) and their 95% CIs.
RESULTS RESULTS
Of 2,027 CC patients, the overall mortality incidence rate was 12.44 per 100 person-years (95% CI: 11.7 - 13.22), median survival time was 4.82 years (95% CI: 3.92 - 5.72), and 10-year survival rate was 43.16% (95% CI: 40.71 - 45.59). The highest 10-year survival rate was 87.85% (95% CI: 82.23 - 91.78) found among those with stage I CC, followed by those who received surgical treatment, which was 81.22% (95% CI: 74.47 - 86.35). Factors that were associated with decreased survival included age ≥60 years (AHR = 1.25; 95% CI: 1.07 - 1.46), health insurance with the Universal Health Coverage Scheme (UCS) (AHR = 6.26; 95% CI: 5.13 - 7.64), malignant neoplasms histopathology (AHR = 1.36; 95% CI: 1.07 - 1.74), and treatment with supportive care (AHR = 7.48; 95% CI: 5.22 - 10.71).
CONCLUSION CONCLUSIONS
Among patients diagnosed with CC, those with stage I had the highest 10-year survival rate. CC patients with older age, UCS, malignant neoplasms histopathology, and received supportive care showed the highest survival association.

Identifiants

pubmed: 37247299
doi: 10.31557/APJCP.2023.24.5.1759
pmc: PMC10495886
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1759-1767

Références

J Gynecol Oncol. 2015 Oct;26(4):293-302
pubmed: 26197770
Diagnostics (Basel). 2021 Mar 22;11(3):
pubmed: 33810019
Obstet Gynecol Sci. 2021 Sep;64(5):444-453
pubmed: 34399564
Asian Pac J Cancer Prev. 2020 Oct 01;21(10):2895-2902
pubmed: 33112546
J Gynecol Oncol. 2018 Mar;29(2):e23
pubmed: 29400016
Asian Pac J Cancer Prev. 2015;16(18):8541-51
pubmed: 26745114
Int J Environ Res Public Health. 2021 Apr 26;18(9):
pubmed: 33926019
J Gynecol Oncol. 2020 May;31(3):e55
pubmed: 32266804
Saudi Med J. 2021 Mar;42(3):338-341
pubmed: 33632914
PLoS One. 2022 Jun 28;17(6):e0270670
pubmed: 35763509
N Engl J Med. 2018 Nov 15;379(20):1955-1957
pubmed: 30379600
Int J Gynaecol Obstet. 2021 Jan;152(1):48-52
pubmed: 33181003
Eur Rev Med Pharmacol Sci. 2021 Jan;25(2):696-709
pubmed: 33577024
Curr Probl Cancer. 2018 Mar - Apr;42(2):161-174
pubmed: 29706467
Glob Health Action. 2017;10(1):1337341
pubmed: 28649938
Asian Pac J Cancer Prev. 2021 Sep 01;22(9):2987-2993
pubmed: 34582671
Asian Pac J Cancer Prev. 2013;14(9):5355-60
pubmed: 24175825
Ann Epidemiol. 2016 Jan;26(1):28-35
pubmed: 26552330
J Obstet Gynaecol Res. 2019 Feb;45(2):289-298
pubmed: 30426591
J Gynecol Oncol. 2022 Sep;33(5):e58
pubmed: 35712971
Springerplus. 2016 Nov 10;5(1):1952
pubmed: 27933235
Gynecol Oncol Rep. 2020 Nov 04;34:100669
pubmed: 33251314
Int J Gynaecol Obstet. 2021 Oct;155 Suppl 1:102-106
pubmed: 34669201
Ann Saudi Med. 2020 Jan-Feb;40(1):25-35
pubmed: 32026705
Brachytherapy. 2019 Jan - Feb;18(1):29-37
pubmed: 30361045
Asian Pac J Cancer Prev. 2019 Feb 26;20(2):369-375
pubmed: 30803194
Asian Pac J Cancer Prev. 2021 Oct 01;22(10):3171-3179
pubmed: 34710993
Asian Pac J Cancer Prev. 2020 Oct 01;21(10):2979-2986
pubmed: 33112557

Auteurs

Rakwarinn Wannasin (R)

Doctor of Public Health Program, Faculty of Public Health, Khon Kaen University, Khon Kaen, Thailand.

Naratassapol Likitdee (N)

Department of Obstetrics and Gynecology, Srinagarind Hospital, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.

Matthew Kelly (M)

Department of Global Health, National Centre for Epidemiology and Population Health, Australian National University, Canberra, Australia.

Kavin Thinkhamrop (K)

Health and Epidemiology Geoinformatics Research (HEGER), Faculty of Public Health, Khon Kaen University, Khon Kaen, Thailand.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH